Study of Diabetes treatment management across region by different investigator for both type 1 & type 2 diabetes patients
Not Applicable
- Conditions
- Health Condition 1: E089- Diabetes mellitus due to underlying condition without complications
- Registration Number
- CTRI/2019/03/017914
- Lead Sponsor
- Sanofi India Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Cross sectional phase
- All male and female adults (with lower legal age limitations (country specific) diagnosed with type 1 or type 2 diabetes, visiting the physician during the recruitment period of the cross-sectional study, up to the number of patients allocated to the physician.
- Written informed consent
2. Longitudinal phase
- Each patient will be asked to enter into the 9-month follow-up period
Exclusion Criteria
1. Cross sectional phase
- Concomitant participation in a clinical trial.
- Current temporary insulin therapy (eg, gestational diabetes, surgery, pancreas cancer)
2. Longitudinal phase
- Concomitant participation in clinical trial.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The global proportion of patients with T2DM treated with insulinTimepoint: 9 months
- Secondary Outcome Measures
Name Time Method The management of care of patients with type 2 diabetes (T2DM) (CS) will be illustrated <br/ ><br>by: <br/ ><br>1.The proportion of T2DM patients achieving glycemic targets (HbA1c) as per recommendations of International guidelines and as targeted by the treating physician. <br/ ><br>Timepoint: 9 Months